High Throughput Bioreactor Considerations for High-Rise Gene Therapy Facilities
The growing expansion of gene therapy research in urban laboratory facilities presents a tremendous opportunity for high-throughput bioreactor applications. Recent advancements in bioreactor automation have improved lab efficiency and provided a critical experimental advantage in early discovery and process development work. These high throughput bioreactors can reduce risk while simultaneously affording greater scalability potential in the run-up to full manufacturing process designs.
From a laboratory design standpoint, two particular challenges should be considered when integrating bioreactors. First, space availability in an urban setting can limit laboratory footprint configurations -- placing a premium on equipment layout efficiency. Next, building code limitations exert a considerable challenge in providing a continuous and reliable high-purity oxygen supply for bioreactors. This article will explore the interrelationship of high-rise laboratory design applications as they apply to bioreactor use.
About IPS IPS
is a global leader in developing innovative business solutions for the biotechnology and pharmaceutical industries. Through operational expertise and industry-leading knowledge, skill, and passion, IPS provides consultancy services, architecture, engineering, project controls, construction management, and compliance services that allow clients to develop and manufacture life-impacting products. Its Canada region, established in 2017, has approximately 100 employees and is growing. With the addition of its newest acquisition, Linesight, IPS has nearly 3,000 professionals in over 45 offices across 17 countries in the Americas, Europe, Asia Pacific, Southeast Asia, Australia, and the Middle East. For further information, please visit IPS.
